FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

The FDA approved Amtagvi, the first cellular therapy for the treatment of adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

Related Keywords

Peter Marks ,Nicole Verdun ,Office Of Therapeutic Products ,Human Services ,Drug Administration ,Us Department Of Health ,Amtagvi To Iovance Biotherapeutics Inc ,For Immediate Release ,Biologics Evaluation ,Therapeutic Products ,Accelerated Approval ,Boxed Warning ,Orphan Drug ,Regenerative Medicine Advanced Therapy ,Fast Track ,Priority Review ,